From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Commentary|Articles|June 23, 2026
ADA 2026: Obesity Pharmacotherapy and the Future of Weight Management
Fact checked by: Gillian McGovern, Editor
Understanding this rapidly evolving therapeutic landscape will be essential as obesity pharmacotherapy continues to transform diabetes and cardiometabolic care.
Advertisement
Advertisement
If there was one therapeutic area that generated excitement throughout the 86th American Diabetes Association (ADA) Scientific Sessions, it was obesity pharmacotherapy. While glucagon-like peptide (GLP)-1 receptor agonists transformed obesity treatment over the past several years, ADA 2026 provided a glimpse into what may come next: triple agonists, amylin analogues, dual GLP-1/glucagon therapies, and next-generation combination approaches capable of producing unprecedented weight loss while improving glycemic control and cardiometabolic health.
Related to this article
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
Advertisement
Advertisement